Evaluation of Definitive Stereotactic Body Radiotherapy and Outcomes in Adults With Extracranial Oligometastasis

This case series reports overall progression-free survival, widespread progression outcomes, and prognostic survival factors from a pooled data set of 1033 patients with oligometastasis treated with stereotactic body radiotherapy.

[1]  B. Yaremko,et al.  Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial , 2020, medRxiv.

[2]  L. Collette,et al.  Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. , 2020, The Lancet. Oncology.

[3]  A. Louie,et al.  A Review of Ongoing Trials of Stereotactic Ablative Radiotherapy for Oligometastatic Cancers: Where Will the Evidence Lead? , 2019, Front. Oncol..

[4]  Michael Lock,et al.  Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial , 2019, The Lancet.

[5]  J. Lee,et al.  Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  B. Loo,et al.  SABR-COMET: harbinger of a new cancer treatment paradigm , 2019, The Lancet.

[7]  W. Tomé,et al.  Immunomodulatory Effects of Stereotactic Body Radiation Therapy: Preclinical Insights and Clinical Opportunities. , 2019, International journal of radiation oncology, biology, physics.

[8]  M. Parmar,et al.  Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial , 2018, The Lancet.

[9]  Joe Y. Chang,et al.  Time to abandon single-site irradiation for inducing abscopal effects , 2018, Nature Reviews Clinical Oncology.

[10]  E. Goetghebeur,et al.  Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  D. Palma,et al.  Definitive Stereotactic Body Radiotherapy (SBRT) for Extracranial Oligometastases: An International Survey of >1000 Radiation Oncologists , 2017, American journal of clinical oncology.

[12]  F. Lohr,et al.  A multinational report of technical factors on stereotactic body radiotherapy for oligometastases. , 2017, Future oncology.

[13]  J. Lee,et al.  Local Consolidative Therapy versus Maintenance Therapy/Observation for Patients with Oligometastatic Non-Small Cell Lung Cancer without Progression after Front-Line Systemic Therapy: Results of a Multi-Institutional Phase II Randomized Study , 2016, The Lancet. Oncology.

[14]  Charles Swanton,et al.  Metastasis as an evolutionary process , 2016, Science.

[15]  F. Lohr,et al.  A multi-national report on stereotactic body radiotherapy for oligometastases: Patient selection and follow-up* , 2016, Acta oncologica.

[16]  David A. Palma,et al.  The oligometastatic state—separating truth from wishful thinking , 2014, Nature Reviews Clinical Oncology.

[17]  A. Bezjak,et al.  The Canadian Association of Radiation Oncology scope of practice guidelines for lung, liver and spine stereotactic body radiotherapy. , 2012, Clinical oncology (Royal College of Radiologists (Great Britain)).

[18]  P. Okunieff,et al.  Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. , 2012, International journal of radiation oncology, biology, physics.

[19]  B. Nordlinger,et al.  Long‐term survival following resection of colorectal hepatic metastases , 1997, The British journal of surgery.

[20]  P. Iyengar,et al.  Consolidative Radiotherapy for Limited Metastatic Non–Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial , 2018, JAMA oncology.

[21]  M Buyse,et al.  Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. , 1997, The Journal of thoracic and cardiovascular surgery.